WP
SGMT icon

Woodline Partners’s Sagimet Biosciences SGMT Stock Holding History

Woodline Partners’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.2M Buy
3,000,652
+1,999,709
+200% +$13.6M 0.07% 336
2026
Q1 		$5.23M Hold
1,000,943
– – 0.02% 652
2025
Q4 		$5.93M Sell
1,000,943
-500,414
-33% -$3.6M 0.02% 589
2025
Q3 		$10.3M Sell
1,501,357
-1,051,179
-41% -$8.52M 0.05% 436
2025
Q2 		$19.5M Buy
+2,552,536
New +$10.8M 0.1% 298
2024
Q2 		– Sell
-300,170
Closed -$1.63M – 658
2024
Q1 		$1.63M Buy
300,170
+1
+0% +$7 0.02% 437
2023
Q4 		$1.63M Sell
300,169
-2
-0% -$9 0.02% 389
2023
Q3 		$2.64M Buy
+300,171
New +$4M 0.03% 374

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Woodline Partners's SGMT Position: Q2 2026 in Review

Woodline Partners increased its Sagimet Biosciences (SGMT) stake by 200% in Q2 2026, buying an estimated $13.6M and bringing the position to 3,000,652 shares worth $23.2M. The position accounts for 0.07% of the portfolio, ranked #336.

Woodline Partners first reported a position in SGMT in Q3 2023 and has held it in 8 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Woodline Partners held 3,000,652 shares of Sagimet Biosciences worth $23.2M as of Q2 2026.
  • Woodline Partners bought 1,999,709 Sagimet Biosciences shares in Q2 2026, an estimated $13.6M.
  • Sagimet Biosciences made up 0.07% of Woodline Partners's portfolio in Q2 2026, its #336 holding.
  • Woodline Partners first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 8 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.